@mikebrisy I have served up a large scoop of wishful thinking on this one, myself.

I am trying to inject some realism/scepticism.

Perhaps this was not the report in which to be getting into the weeds on the PEP.

The market and I are hungry for some sales data.

Hi Arizona, I think they only ran the very limited PEP based on the sales numbers and were behind the timeline.

I feel like they aren't doing the full Ihhs rollout unless that only started in Jan and have just proceeded to the sales rep rollout.

It does annoy me that there was all the talk of that phase of the rollout and now it's just a small note that they all got their refills but no details.

They were also supposed to start that 1m patient high priority list which isn't mentioned either.

The only good takeaway is the 221,000 units of stock or thereabouts (working on $50usd / unit) ready to go.

Still think they shoot the lights out based on what Kaken have done.. I have a minor concern about the side effects of the 15% vs the 5% used in Japan but I think that can be sorted by patients using a half pump (saw someone in Reddit mentioning the side effects they had) in the Argyl study Brickell did the 15% gel was only slightly more effective but a bit spicier on side effects)

Held IRL and SM

@Schwerms If memory serves, there was 18,000 members in the IHHS and something like 500 people showed interest in the PEP - correct me if I am wrong.

So really there may have been a few hundred participants in the PEP at best. It was never going to be a huge data set, but it was something to base models off, as the Japanese sales have been.

Perhaps as @mikebrisy says, there will be an announcement shortly getting into these results?

I hope so, if you do the numbers on the 4c revenue I think it worked out to 50 people.. I would have to double check though as you have to estimate what Kaken contributed but it looked more like 50 than 500.

Just another 2 months of waiting Arizona.. the hardest part of investing.

I feel a bit the same @Arizona , I had a quick glance pre-opening, hoping we would get a serious update and when it seemed like that wasn't the case I had some concerns as to why. However @mikebrisy makes a good point, they are probably working on something more presentable on the matter and a half year report is relatively basic, but a half year report presentation that they are probably working on gives them a lot more latitude for a current situation update and details.

Still, I was hang out for at least some sort of update from them this week. Until then the BOT half year report gets added to the long list I will review in detail and update my workpapers on.

Maybe that will be in their typical Feb 28th slot as they were 2 days earlier than normal with the half year. I've resigned myself to the fact April 30 is the next significant update so anything earlier will be a bonus.

We still haven't seen the Euroz Hartley's 2025 content, they were on the list and there was another website with a note but no presentation material or even mention of it by them when other companies released notes about presenting..